Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR

由 Zhou, Xiuman, Du, Jiangfeng, Wang, Hongfei, Chen, Chunxia, Jiao, Ling, Cheng, Xiangrui, Zhou, Xiaowen, Chen, Shaomeng, Gou, Shanshan, Zhao, Wenshan, Zhai, Wenjie, Chen, Junhui, Gao, Yanfeng
發表在 Cell Commun Signal (2020)

Adjuvant-free peptide vaccine targeting Clec9a on dendritic cells can induce robust antitumor immune response through Syk/IL-21 axis

由 Gou, Shanshan, Wang, Shuai, Liu, Wenwen, Chen, Guanyu, Zhang, Dongyang, Du, Jiangfeng, Yan, Zhongyi, Wang, Hongfei, Zhai, Wenjie, Sui, Xinghua, Wu, Yahong, Qi, Yuanming, Gao, Yanfeng
發表在 Theranostics (2021)

CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy

由 Wang, Hongfei, Sun, Yixuan, Zhou, Xiuman, Chen, Chunxia, Jiao, Ling, Li, Wanqiong, Gou, Shanshan, Li, Yanying, Du, Jiangfeng, Chen, Guanyu, Zhai, Wenjie, Wu, Yahong, Qi, Yuanming, Gao, Yanfeng
發表在 J Immunother Cancer (2020)

Computer-aided design of PVR mutants with enhanced binding affinity to TIGIT

由 Zhou, Xiaowen, Du, Jiangfeng, Zhou, Xiuman, Niu, Xiaoshuang, Li, Wanqiong, Chen, Chunxia, Lv, Sifan, Wu, Aijun, Gou, Shanshan, Sun, Yixuan, Zhai, Wenjie, Qiu, Lu, Qi, Yuanming, Zhao, Wenshan, Gao, Yanfeng
發表在 Cell Commun Signal (2021)